Characteristic |
Overall, N = 108 1 |
IV, N = 60 1 |
PO, N = 48 1 |
p-value 2 |
|---|---|---|---|---|
| out_vs_inpatient | 0.2 | |||
| 13 (22%) | 5 (17%) | 8 (28%) | ||
| 0 | 33 (57%) | 20 (69%) | 13 (45%) | |
| 1 | 12 (21%) | 4 (14%) | 8 (28%) | |
| pre_hr | 75 (69, 83) | 77 (73, 85) | 75 (66, 81) | 0.057 |
| pre_sbp | 136 (127, 146) | 136 (128, 144) | 135 (125, 147) | >0.9 |
| pre_dbp | 81 (74, 88) | 82 (74, 88) | 81 (75, 88) | >0.9 |
| rhythm | 0.8 | |||
| 0 | 101 (94%) | 55 (92%) | 46 (96%) | |
| 1 | 4 (3.7%) | 3 (5.0%) | 1 (2.1%) | |
| 2 | 3 (2.8%) | 2 (3.3%) | 1 (2.1%) | |
| metoprolol_dose | 0 (0, 50) | 0 (0, 0) | 50 (50, 50) | <0.001 |
| ivabridine_dose | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 1.25) | <0.001 |
| iv_metoprolol | 5.0 (0.0, 10.0) | 10.0 (5.0, 10.0) | 0.0 (0.0, 0.0) | <0.001 |
| post_hr | 63 (56, 69) | 64 (58, 69) | 62 (54, 68) | 0.3 |
| post_hr_variability | 0.85 (0.00, 1.40) | 0.85 (0.00, 1.68) | 0.80 (0.00, 1.40) | 0.3 |
| post_sbp | 124 (114, 133) | 122 (115, 129) | 130 (114, 141) | 0.049 |
| post_dbp | 72 (69, 78) | 71 (68, 76) | 73 (69, 80) | 0.054 |
| age | 55 (46, 65) | 53 (44, 66) | 56 (49, 61) | 0.7 |
| bmi | 31 (25, 36) | 29 (26, 36) | 33 (25, 35) | 0.7 |
| dlp_m_gycm | 468 (312, 648) | 486 (300, 648) | 460 (351, 603) | 0.7 |
| m_sv | 6.5 (4.6, 8.3) | 6.8 (4.2, 9.0) | 6.5 (5.1, 8.0) | 0.9 |
| protocol | >0.9 | |||
| 1 | 19 (18%) | 12 (21%) | 7 (15%) | |
| 2 | 46 (43%) | 23 (40%) | 23 (48%) | |
| 3 | 5 (4.7%) | 3 (5.2%) | 2 (4.2%) | |
| 4 | 9 (8.5%) | 5 (8.6%) | 4 (8.3%) | |
| 5 | 20 (19%) | 11 (19%) | 9 (19%) | |
| 6 | 3 (2.8%) | 2 (3.4%) | 1 (2.1%) | |
| 7 | 4 (3.8%) | 2 (3.4%) | 2 (4.2%) | |
| table_time_min | 25 (18, 31) | 30 (25, 35) | 19 (15, 22) | <0.001 |
| repeat_study | 6 (5.6%) | 5 (8.3%) | 1 (2.1%) | 0.2 |
| side_effects | 0 (0%) | 0 (0%) | 0 (0%) | |
| below_70_hr | 82 (77%) | 45 (78%) | 37 (77%) | >0.9 |
| retro_vs_prospective | >0.9 | |||
| prospective | 73 (69%) | 40 (69%) | 33 (69%) | |
| retro | 33 (31%) | 18 (31%) | 15 (31%) | |
| axial_vs_helical | >0.9 | |||
| axial | 70 (66%) | 38 (66%) | 32 (67%) | |
| helical | 36 (34%) | 20 (34%) | 16 (33%) | |
| 1
n (%); Median (IQR) |
||||
| 2
Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test |
||||
dan_qi - AFIB IS NOT REMOVED
Smaller comparisons - IV helical vs. PO helical
Characteristic |
Overall, N = 36 1 |
IV, N = 20 1 |
PO, N = 16 1 |
p-value 2 |
|---|---|---|---|---|
| out_vs_inpatient | >0.9 | |||
| 2 (13%) | 0 (0%) | 2 (20%) | ||
| 0 | 11 (73%) | 4 (80%) | 7 (70%) | |
| 1 | 2 (13%) | 1 (20%) | 1 (10%) | |
| pre_hr | 79 (74, 88) | 80 (76, 88) | 76 (69, 88) | 0.4 |
| pre_sbp | 130 (122, 142) | 130 (119, 142) | 131 (122, 141) | >0.9 |
| pre_dbp | 80 (71, 85) | 79 (71, 85) | 81 (73, 86) | 0.5 |
| rhythm | >0.9 | |||
| 0 | 32 (89%) | 17 (85%) | 15 (94%) | |
| 1 | 3 (8.3%) | 2 (10%) | 1 (6.3%) | |
| 2 | 1 (2.8%) | 1 (5.0%) | 0 (0%) | |
| metoprolol_dose | 0 (0, 50) | 0 (0, 0) | 50 (44, 50) | <0.001 |
| ivabridine_dose | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 5.0) | 0.009 |
| iv_metoprolol | 5.0 (0.0, 10.0) | 10.0 (5.0, 10.0) | 0.0 (0.0, 0.0) | <0.001 |
| post_hr | 66 (59, 74) | 66 (59, 73) | 66 (59, 76) | 0.8 |
| post_hr_variability | 0.00 (0.00, 0.53) | 0.00 (0.00, 0.20) | 0.00 (0.00, 0.53) | >0.9 |
| post_sbp | 123 (112, 132) | 119 (110, 127) | 129 (120, 135) | 0.088 |
| post_dbp | 72 (68, 77) | 71 (66, 76) | 73 (69, 81) | 0.2 |
| age | 55 (47, 68) | 64 (46, 71) | 53 (50, 66) | 0.8 |
| bmi | 28 (24, 37) | 28 (23, 37) | 29 (25, 37) | 0.7 |
| dlp_m_gycm | 651 (297, 978) | 697 (337, 1,026) | 499 (291, 947) | 0.5 |
| m_sv | 9.0 (4.2, 12.2) | 9.3 (4.5, 13.1) | 7.0 (4.8, 11.8) | 0.6 |
| protocol | >0.9 | |||
| 4 | 9 (25%) | 5 (25%) | 4 (25%) | |
| 5 | 20 (56%) | 11 (55%) | 9 (56%) | |
| 6 | 3 (8.3%) | 2 (10%) | 1 (6.3%) | |
| 7 | 4 (11%) | 2 (10%) | 2 (13%) | |
| table_time_min | 23 (17, 30) | 29 (24, 35) | 17 (14, 21) | <0.001 |
| repeat_study | 1 (2.8%) | 1 (5.0%) | 0 (0%) | >0.9 |
| side_effects | 0 (0%) | 0 (0%) | 0 (0%) | |
| below_70_hr | 22 (61%) | 12 (60%) | 10 (63%) | 0.9 |
| retro_vs_prospective | >0.9 | |||
| prospective | 3 (8.3%) | 2 (10%) | 1 (6.3%) | |
| retro | 33 (92%) | 18 (90%) | 15 (94%) | |
| axial_vs_helical | ||||
| helical | 36 (100%) | 20 (100%) | 16 (100%) | |
| 1
n (%); Median (IQR) |
||||
| 2
Fisher’s exact test; Wilcoxon rank sum test; Pearson’s Chi-squared test |
||||
Smaller comparisons - IV axial vs. PO axial.
Characteristic |
Overall, N = 70 1 |
IV, N = 38 1 |
PO, N = 32 1 |
p-value 2 |
|---|---|---|---|---|
| out_vs_inpatient | 0.031 | |||
| 9 (22%) | 3 (14%) | 6 (32%) | ||
| 0 | 22 (54%) | 16 (73%) | 6 (32%) | |
| 1 | 10 (24%) | 3 (14%) | 7 (37%) | |
| pre_hr | 75 (67, 79) | 75 (70, 80) | 71 (65, 79) | 0.14 |
| pre_sbp | 137 (129, 148) | 137 (130, 144) | 137 (129, 149) | >0.9 |
| pre_dbp | 83 (76, 89) | 83 (76, 89) | 81 (77, 88) | 0.7 |
| rhythm | >0.9 | |||
| 0 | 68 (97%) | 37 (97%) | 31 (97%) | |
| 2 | 2 (2.9%) | 1 (2.6%) | 1 (3.1%) | |
| metoprolol_dose | 0 (0, 50) | 0 (0, 0) | 50 (50, 50) | <0.001 |
| ivabridine_dose | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.003 |
| iv_metoprolol | 5.0 (0.0, 10.0) | 10.0 (5.0, 10.0) | 0.0 (0.0, 0.0) | <0.001 |
| post_hr | 62 (56, 67) | 64 (58, 67) | 61 (53, 65) | 0.075 |
| post_hr_variability | 1.20 (0.73, 1.68) | 1.20 (0.80, 1.78) | 1.20 (0.60, 1.40) | 0.3 |
| post_sbp | 125 (115, 136) | 122 (117, 130) | 130 (114, 147) | 0.3 |
| post_dbp | 72 (69, 78) | 72 (69, 76) | 73 (69, 80) | 0.15 |
| age | 55 (45, 61) | 51 (43, 61) | 57 (49, 61) | 0.4 |
| bmi | 31.5 (26.3, 34.8) | 30.5 (26.3, 35.3) | 33.0 (26.5, 34.3) | 0.6 |
| dlp_m_gycm | 425 (326, 526) | 427 (300, 526) | 424 (363, 525) | 0.8 |
| m_sv | 5.95 (4.60, 7.33) | 5.95 (4.23, 7.38) | 5.95 (5.10, 7.13) | 0.8 |
| protocol | 0.7 | |||
| 1 | 19 (27%) | 12 (32%) | 7 (22%) | |
| 2 | 46 (66%) | 23 (61%) | 23 (72%) | |
| 3 | 5 (7.1%) | 3 (7.9%) | 2 (6.3%) | |
| table_time_min | 25 (20, 31) | 30 (25, 34) | 20 (15, 22) | <0.001 |
| repeat_study | 3 (4.3%) | 2 (5.3%) | 1 (3.1%) | >0.9 |
| side_effects | 0 (0%) | 0 (0%) | 0 (0%) | |
| below_70_hr | 60 (86%) | 33 (87%) | 27 (84%) | >0.9 |
| retro_vs_prospective | ||||
| prospective | 70 (100%) | 38 (100%) | 32 (100%) | |
| axial_vs_helical | ||||
| axial | 70 (100%) | 38 (100%) | 32 (100%) | |
| 1
n (%); Median (IQR) |
||||
| 2
Fisher’s exact test; Wilcoxon rank sum test |
||||
Smaller comparisons - IV helical vs. IV axial
Characteristic |
Overall, N = 58 1 |
axial, N = 38 1 |
helical, N = 20 1 |
p-value 2 |
|---|---|---|---|---|
| out_vs_inpatient | >0.9 | |||
| 3 (11%) | 3 (14%) | 0 (0%) | ||
| 0 | 20 (74%) | 16 (73%) | 4 (80%) | |
| 1 | 4 (15%) | 3 (14%) | 1 (20%) | |
| pre_hr | 76 (72, 83) | 75 (70, 80) | 80 (76, 88) | 0.014 |
| pre_sbp | 136 (127, 144) | 137 (130, 144) | 130 (119, 142) | 0.15 |
| pre_dbp | 82 (74, 88) | 83 (76, 89) | 79 (71, 85) | 0.2 |
| rhythm | 0.11 | |||
| 0 | 54 (93%) | 37 (97%) | 17 (85%) | |
| 1 | 2 (3.4%) | 0 (0%) | 2 (10%) | |
| 2 | 2 (3.4%) | 1 (2.6%) | 1 (5.0%) | |
| po_vs_iv | 0 (0%) | 0 (0%) | 0 (0%) | |
| metoprolol_dose | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | 0.5 |
| ivabridine_dose | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | |
| iv_metoprolol | 10.0 (5.0, 10.0) | 10.0 (5.0, 10.0) | 10.0 (5.0, 10.0) | >0.9 |
| post_hr | 64 (58, 69) | 64 (58, 67) | 66 (59, 73) | 0.3 |
| post_hr_variability | 0.85 (0.00, 1.68) | 1.20 (0.80, 1.78) | 0.00 (0.00, 0.20) | <0.001 |
| post_sbp | 122 (115, 129) | 122 (117, 130) | 119 (110, 127) | 0.2 |
| post_dbp | 71 (68, 76) | 72 (69, 76) | 71 (66, 76) | 0.7 |
| age | 53 (44, 66) | 51 (43, 61) | 64 (46, 71) | 0.14 |
| bmi | 29.0 (25.0, 36.0) | 30.5 (26.3, 35.3) | 28.0 (23.0, 36.5) | 0.5 |
| dlp_m_gycm | 486 (300, 648) | 427 (300, 526) | 697 (337, 1,026) | 0.016 |
| m_sv | 6.8 (4.2, 9.0) | 6.0 (4.2, 7.4) | 9.3 (4.5, 13.1) | 0.030 |
| protocol | <0.001 | |||
| 1 | 12 (21%) | 12 (32%) | 0 (0%) | |
| 2 | 23 (40%) | 23 (61%) | 0 (0%) | |
| 3 | 3 (5.2%) | 3 (7.9%) | 0 (0%) | |
| 4 | 5 (8.6%) | 0 (0%) | 5 (25%) | |
| 5 | 11 (19%) | 0 (0%) | 11 (55%) | |
| 6 | 2 (3.4%) | 0 (0%) | 2 (10%) | |
| 7 | 2 (3.4%) | 0 (0%) | 2 (10%) | |
| table_time_min | 30 (25, 35) | 30 (25, 34) | 29 (24, 35) | 0.6 |
| repeat_study | 3 (5.2%) | 2 (5.3%) | 1 (5.0%) | >0.9 |
| side_effects | 0 (0%) | 0 (0%) | 0 (0%) | |
| below_70_hr | 45 (78%) | 33 (87%) | 12 (60%) | 0.043 |
| retro_vs_prospective | <0.001 | |||
| prospective | 40 (69%) | 38 (100%) | 2 (10%) | |
| retro | 18 (31%) | 0 (0%) | 18 (90%) | |
| 1
n (%); Median (IQR) |
||||
| 2
Fisher’s exact test; Wilcoxon rank sum test; Wilcoxon rank sum exact test; Pearson’s Chi-squared test |
||||
Smaller comparisons - PO helical vs. PO axial
Characteristic |
Overall, N = 48 1 |
axial, N = 32 1 |
helical, N = 16 1 |
p-value 2 |
|---|---|---|---|---|
| out_vs_inpatient | 0.2 | |||
| 8 (28%) | 6 (32%) | 2 (20%) | ||
| 0 | 13 (45%) | 6 (32%) | 7 (70%) | |
| 1 | 8 (28%) | 7 (37%) | 1 (10%) | |
| pre_hr | 75 (66, 81) | 71 (65, 79) | 76 (69, 88) | 0.10 |
| pre_sbp | 135 (125, 147) | 137 (129, 149) | 131 (122, 141) | 0.3 |
| pre_dbp | 81 (75, 88) | 81 (77, 88) | 81 (73, 86) | 0.9 |
| rhythm | 0.6 | |||
| 0 | 46 (96%) | 31 (97%) | 15 (94%) | |
| 1 | 1 (2.1%) | 0 (0%) | 1 (6.3%) | |
| 2 | 1 (2.1%) | 1 (3.1%) | 0 (0%) | |
| po_vs_iv | 48 (100%) | 32 (100%) | 16 (100%) | |
| metoprolol_dose | 50 (50, 50) | 50 (50, 50) | 50 (44, 50) | 0.8 |
| ivabridine_dose | 0.00 (0.00, 1.25) | 0.00 (0.00, 0.00) | 0.00 (0.00, 5.00) | 0.3 |
| iv_metoprolol | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | 0.0000 (0.0000, 0.0000) | |
| post_hr | 62 (54, 68) | 61 (53, 65) | 66 (59, 76) | 0.050 |
| post_hr_variability | 0.80 (0.00, 1.40) | 1.20 (0.60, 1.40) | 0.00 (0.00, 0.53) | 0.002 |
| post_sbp | 130 (114, 141) | 130 (114, 147) | 129 (120, 135) | 0.9 |
| post_dbp | 73 (69, 80) | 73 (69, 80) | 73 (69, 81) | >0.9 |
| age | 56 (49, 61) | 57 (49, 61) | 53 (50, 66) | >0.9 |
| bmi | 33 (25, 35) | 33 (27, 34) | 29 (25, 37) | 0.9 |
| dlp_m_gycm | 460 (351, 603) | 424 (363, 525) | 499 (291, 947) | 0.2 |
| m_sv | 6.5 (5.1, 8.0) | 6.0 (5.1, 7.1) | 7.0 (4.8, 11.8) | 0.14 |
| protocol | <0.001 | |||
| 1 | 7 (15%) | 7 (22%) | 0 (0%) | |
| 2 | 23 (48%) | 23 (72%) | 0 (0%) | |
| 3 | 2 (4.2%) | 2 (6.3%) | 0 (0%) | |
| 4 | 4 (8.3%) | 0 (0%) | 4 (25%) | |
| 5 | 9 (19%) | 0 (0%) | 9 (56%) | |
| 6 | 1 (2.1%) | 0 (0%) | 1 (6.3%) | |
| 7 | 2 (4.2%) | 0 (0%) | 2 (13%) | |
| table_time_min | 18.5 (14.8, 22.0) | 19.5 (15.0, 22.0) | 17.0 (13.8, 20.8) | 0.4 |
| repeat_study | 1 (2.1%) | 1 (3.1%) | 0 (0%) | >0.9 |
| side_effects | 0 (0%) | 0 (0%) | 0 (0%) | |
| below_70_hr | 37 (77%) | 27 (84%) | 10 (63%) | 0.14 |
| retro_vs_prospective | <0.001 | |||
| prospective | 33 (69%) | 32 (100%) | 1 (6.3%) | |
| retro | 15 (31%) | 0 (0%) | 15 (94%) | |
| 1
n (%); Median (IQR) |
||||
| 2
Fisher’s exact test; Wilcoxon rank sum test; Pearson’s Chi-squared test |
||||